Company / CapEx per Share
VYNE Therapeutics Inc. CapEx per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.01
FY2025
5-year range
$0.00 / $0.01
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
CapEx per Share returned to growth in FY2025 after 2 years of decline, reaching $0.01.
Based on SEC 10-K filings.
0.01 in FY2025 with a 5-year CAGR of -33.8%.
Improved from $0.00 to $0.01 over the past 4 years.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -33.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- Peak capex per share was recorded in FY2020.
- Lowest capex per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.01 | - |
| FY2024 | $0.00 | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $0.00 | -95.8% |
| FY2020 | $0.06 | +5249.7% |
| FY2019 | $0.00 | -80.1% |
| FY2018 | $0.01 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026